Compare · ABT vs BRNS
ABT vs BRNS
Side-by-side comparison of Abbott Laboratories (ABT) and Barinthus Biotherapeutics plc (BRNS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and BRNS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $152.98B, about 5367.0x BRNS ($28.5M).
- Over the past year, ABT is down 34.1% and BRNS is down 17.9% - BRNS leads by 16.3 points.
- ABT has been more active in the news (5 items in the past 4 weeks vs 1 for BRNS).
- ABT has more recent analyst coverage (25 ratings vs 0 for BRNS).
- Company
- Abbott Laboratories
- Barinthus Biotherapeutics plc
- Price
- $87.77-0.74%
- $0.69+1.47%
- Market cap
- $152.98B
- $28.5M
- 1M return
- -0.68%
- +2.24%
- 1Y return
- -34.11%
- -17.86%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 5
- 1
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Director Stratton John G bought $173,640 worth of Common shares without par value (2,000 units at $86.82), increasing direct ownership by 9% to 23,319 units (SEC Form 4)
- SEC Form 11-K filed by Abbott Laboratories
- Abbott declares 410th consecutive quarterly dividend
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
Latest BRNS
- SEC Form DEF 14A filed by Barinthus Biotherapeutics plc
- Barinthus Biotherapeutics plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 3 filed by new insider Swirsky Douglas J
- SEC Form 10-Q filed by Barinthus Biotherapeutics plc
- Barinthus Biotherapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments
- SEC Form DEFM14A filed by Barinthus Biotherapeutics plc
- Barinthus Biotherapeutics plc filed SEC Form 8-K: Leadership Update
- Barinthus Biotherapeutics plc filed SEC Form 8-K: Leadership Update
- SEC Form 10-K filed by Barinthus Biotherapeutics plc